Targeted Monoclonal Antibody Therapy for a Rare T-Cell Leukemia
Name of the Trial
Why Is This Trial Important?
However, approximately one half of patients develop complications from T-LGLL that can be life-threatening. Some complications, such as increased susceptibility to infection, anemia, and impaired blood clotting, result from abnormally low numbers of normal white or red blood cells or platelets. Other complications, such as rheumatoid arthritis, result from disturbances in the immune system that cause autoimmune disorders.
Researchers have created a humanized monoclonal antibody, MiK-beta-1, that targets a protein located on the surface of malignant T lymphocytes that is crucial to their continued proliferation. This protein acts as a receptor molecule for interleukin 15, a cytokine that stimulates T-LGLL cell growth. Treatment with MiK-beta-1 may slow or interrupt the abnormal proliferation of T-LGLL cells by blocking the binding of IL-15 to its receptor, perhaps inhibiting disease progression and reducing the severity of some complications.
"This study is designed principally to assess the safety of a single dose of this monoclonal antibody," said Dr. Morris. "If the treatment is tolerated, we hope eventually to use repeated doses of MiK-beta-1 to treat not only T-LGLL, but also certain autoimmune disorders such as rheumatoid arthritis and multiple sclerosis."
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.